Clinical Drug Investigation

Clinical Drug Investigation

临床药物调查

  • 3区 中科院分区
  • Q2 JCR分区

期刊简介

《Clinical Drug Investigation》是由Springer International Publishing出版社于1989年创办的英文国际期刊(ISSN: 1173-2563,E-ISSN: 1179-1918),该期刊长期致力于药学领域的创新研究,主要研究方向为医学-药学。作为SCI、SCIE收录期刊(JCR分区 Q2,中科院 3区),本刊采用OA未开放获取模式(OA占比0.2146...%),以发表药学领域等方向的原创性研究为核心(研究类文章占比67.90%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在81篇,确保学术质量与前沿性。成果覆盖Web of ScienceWeb of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Clinical Drug Investigation审稿周期约为较慢,6-12周。该刊近年未被列入国际预警名单,年发文量约81篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCI、SCIE 期刊收录
  • 81 发文量

中科院分区

《新锐期刊分区表》(2026年3月发布)

Top期刊 综述期刊 大类学科 小类学科
医学
3区
PHARMACOLOGY & PHARMACY 药学
3区

期刊分区表(2025年3月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
3区
PHARMACOLOGY & PHARMACY 药学
3区

期刊分区表(2023年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
3区
PHARMACOLOGY & PHARMACY 药学
3区

期刊分区表(2022年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
3区
PHARMACOLOGY & PHARMACY 药学
3区

期刊分区表(2021年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
4区
PHARMACOLOGY & PHARMACY 药学
4区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q2 163 / 356

54.4

学科:PHARMACOLOGY & PHARMACY SCIE Q2 157 / 356

56.04

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q2 164 / 352

53.6

学科:PHARMACOLOGY & PHARMACY SCIE Q2 140 / 353

60.48

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q2 147 / 354

58.6

学科:PHARMACOLOGY & PHARMACY SCIE Q2 125 / 354

64.83

CiteScore(2026年6月最新版)

CiteScore SJR SNIP CiteScore 排名
CiteScore:5.2 SJR:0.823 SNIP:0.829
学科类别 分区 排名 百分位
大类:Medicine 小类:Pharmacology (medical) Q2 94 / 278

66%

期刊发文

  • Effectiveness of Dexmedetomidine and Sufentanil in Preventing Adverse Reactions to Carboprost Tromethamine During Cesarean Section with Noninvasive Cardiac System Monitorin

    Author: Li, Jing; Xiang, Bo; Lei, Xiaofeng; Yu, Jin

    Journal: CLINICAL DRUG INVESTIGATION. 2026; Vol. 46, Issue 5, pp. 551-559. DOI: 10.1007/s40261-026-01547-x

  • Pharmacokinetics, Safety Profile, and Tolerability of MN-08 Tablets after Single and Multiple Ascending Doses in Healthy Chinese Volunteer

    Author: Yang, Enyue; Chen, Mingxin; Wu, Mingji; Dong, Qi; Li, Jinhua; Xu, Honglan; Qu, Baoju; Zhang, Huazi; Jin, Zhehu; Li, Guantong; Jing, Mei; Zhang, Zaijun; Zhang, Gaoxiao; Piao, Hongxin

    Journal: CLINICAL DRUG INVESTIGATION. 2026; Vol. 46, Issue 4, pp. 391-406. DOI: 10.1007/s40261-026-01522-6

  • Global Long-Term Cost Effectiveness of Newer Antidiabetic Drugs for Type 2 Diabetes Mellitus: A Systematic Revie

    Author: Li, Dan; Smith, Alesha; Marra, Carlo A

    Journal: CLINICAL DRUG INVESTIGATION. 2026; Vol. 46, Issue 4, pp. 359-376. DOI: 10.1007/s40261-026-01530-6

  • Cost-Effectiveness Analysis of PI3K Inhibitors for Relapsed or Refractory Follicular Lymphoma in China: A Comparison Between Linperlisib and Duvelisi

    Author: Bai, Xuefei; Shao, Rongjie; He, Xiaoning

    Journal: CLINICAL DRUG INVESTIGATION. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s40261-026-01532-4

  • Comparison of the Efficacy of Denosumab and Alendronate in Improving Bone Mineral Density in Osteoporosis Patients and High-Risk Populations: A Systematic Review and Meta-Analysi

    Author: Zhu, Kejia; Li, Hang; Zhang, Hui; Zhou, Zongke; Shen, Bin; Nie, Yong

    Journal: CLINICAL DRUG INVESTIGATION. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s40261-025-01521-z

  • A Single-Center, Randomized, Open-Label, Two-Formulation, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of Two Eltrombopag Olamine Tablets (25 mg) in Healthy Chinese Subjects in the Fed Stat

    Author: Wu, Keyi; Ren, Qin; Wang, Yanli; Zhou, Yannan; Liu, Zhengzhi; Cheng, Yang; Deng, Qiaohuan; Cui, Yingzi; Yang, Haimiao

    Journal: CLINICAL DRUG INVESTIGATION. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s40261-026-01528-0

  • Population Pharmacokinetics of SCT510 (a Bevacizumab Biosimilar) and Avastin® in Healthy Subjects and Patients with Non-squamous Non-small Cell Lung Cance

    Author: Hong, Qianqian; Jiao, Yuhuan; Li, Dongyang; Ma, Hongyun; Wu, Kun; Xie, Liangzhi

    Journal: CLINICAL DRUG INVESTIGATION. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s40261-025-01518-8

  • Risk of Ophthalmotoxicity Associated with Antibody-Drug Conjugates: A Systematic Review and Meta-analysi

    Author: Feng, Xin; Yu, Xiaoxia; Yang, Shan; Yuan, Guosen; Huang, Min; He, Zhichao; Wu, Junyan

    Journal: CLINICAL DRUG INVESTIGATION. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s40261-025-01447-6